Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Computing & Software
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Hoffmann-La Roche, Inc. has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 3 distinct examiners and 3 distinct art units. MOSELEY II, NELSON B is the busiest examiner, handling 1 pending office action. The equal distribution of cases across different examiners and art units suggests a diversified prosecution strategy for the company's current patent applications in this sector.
This prosecution profile shows a high degree of diversity, as each of the 3 pending office actions is being reviewed by a different individual in a different administrative unit. Such a spread is beneficial for mitigating the risk associated with any single examiner's tendencies or any single art unit's policies. However, it also requires the practitioner to manage three distinct relationships and sets of procedural expectations. Coordinating claim language across these 3 distinct art units is essential to ensure that the resulting patents provide broad and consistent protection for the company's biotechnology innovations.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 3 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOSELEY II, NELSON B | 1 | 68.0% | +41.5% |
| LAHAM BAUZO, ALVARO SALIM | 1 | 50.0% | +100.0% |
| IANNUZO, NATALIE NMN | 1 | 12.5% | +71.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18020048 | METHOD FOR PRODUCING PROTEIN COMPOSITIONS | IANNUZO, NATALIE NMN | 4d overdue |
| 18035260 | TECHNIQUES FOR GENERATING PREDICTIVE OUTCOMES RELATING TO SPINAL MUSCULAR ATROPHY USING ARTIFICIAL INTELLIGENCE | LAHAM BAUZO, ALVARO SALIM | 12d |
| 18317385 | DUAL TARGETING | MOSELEY II, NELSON B | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18020048 | METHOD FOR PRODUCING PROTEIN COMPOSITIONS | IANNUZO, NATALIE NMN | 4d overdue |
| 18035260 | TECHNIQUES FOR GENERATING PREDICTIVE OUTCOMES RELATING TO SPINAL MUSCULAR ATROPHY USING ARTIFICIAL INTELLIGENCE | LAHAM BAUZO, ALVARO SALIM | 12d |
| 18317385 | DUAL TARGETING | MOSELEY II, NELSON B | — |
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
| 2146 | 1 |
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18317385 | DUAL TARGETING | MOSELEY II, NELSON B | 1642 | §102§112 | Non-Final OA | — | Pending | May 15, 2023 |
| 18035260 | TECHNIQUES FOR GENERATING PREDICTIVE OUTCOMES RELATING TO SPINAL MUSCULAR ATROPHY USING ARTIFICIAL INTELLIGENCE | LAHAM BAUZO, ALVARO SALIM | 2146 | §103§112 | Non-Final OA | 12d | Pending | May 03, 2023 |
| 18020048 | METHOD FOR PRODUCING PROTEIN COMPOSITIONS | IANNUZO, NATALIE NMN | 1653 | §102§103§112 | Final Rejection | 4d overdue | Pending | Feb 06, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial